Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Gastrointestinal 2Thoracic 1Lymphoid 1

Conditions

Polyps 1Liver Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Docosahexaenoic Acids × Gastrointestinal × Clear all
NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

American Regent, Inc.

Phase 2 Terminated
13 enrolled
Gastrointestinal

Liver Neoplasms

NCT03806426 2024-04-25

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

S.L.A. Pharma AG

Phase 3 Unknown
204 enrolled
Gastrointestinal

Adenomatous Polyposis Coli, Polyps

Data powered by HemOnc (CC BY 4.0) Colophon âš¡